TMCnet News
Anxiety Disorders And Depression Treatment Market Analysis 2014 - 2025 - Research and MarketsResearch and Markets has announced the addition of the "Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025" report to their offering. The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years. The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety isorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives. Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period Key Topics Covered: 1 Research Methodology & Scope 2 Executive Summary 3 Anxiety Disorder And Depression Treatment Market Variables, Trends & Scope 4 Market Categorization 1: Product Estimates & Trend Analysis 5 Market Categorization 2: Indication Estimates & Trend Analysis 6 Market Categorization 3: Regional Estimates & Trend Analysis, by Product Type and Indication 7 Competitive Landscape For more information about this report visit http://www.researchandmarkets.com/research/35zr4q/anxiety_disorders View source version on businesswire.com: http://www.businesswire.com/news/home/20170125005622/en/ |
